Systemic Mastocytosis
Conditions
Brief summary
This study is being done to better understand how symptoms of Systemic Mastocytosis (SM) relate to biological signals and to better understand how different treatments affect these signals.
Interventions
None listed
Sponsors
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of indolent systemic mastocytosis as defined by the World Health Organization 2022 criteria. * Doses of baseline treatment medications are stable for ≥ 14 days prior to enrollment. * Patient must have an Eastern Cooperative Oncology Group Performance Status of 0 to 2.
Exclusion criteria
* Diagnosis of advanced systemic mastocytosis defined by established criteria as outlined by the World Health Organization 2022 criteria. * Patient must not have had any cytoreductive therapy including but not limited to cladribine, interferon alpha, pegylated interferon, or antibody therapy \< 28 days prior to enrollment. * Any other significant medical issue as determined by the principal investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participant Completion Rate at 12 Weeks | 12 weeks | Proportion of enrolled participants who remain in the study and complete the 12 weeks of sample and data collection. |
Countries
United States
Contacts
CONTACTLaurie Mulhern
CONTACTKay Bachman
PRINCIPAL_INVESTIGATORThanai Pongdee, MD
Mayo Clinic
Outcome results
None listed